Deerfield Capital

Ascertain is a collaborative venture between Northwell Health and Aegis Ventures, aimed at transforming healthcare through innovative company creation. This organization focuses on systematically developing, launching, and commercializing healthcare AI companies, utilizing a comprehensive platform that integrates medical, technological, data, and business resources. By addressing critical issues related to quality, equity, and cost in healthcare, Ascertain seeks to improve patient care and experience. The organization is dedicated to placing patient needs at the forefront of its business models and technology solutions, ultimately striving to enhance long-term health outcomes and advance the overall quality of care.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Achilles International enables people with all types of disabilities to participate in running events to promote personal achievement.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.

Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies.

Nema Health is focused on delivering comprehensive trauma care through an online platform, specifically designed for individuals affected by post-traumatic stress disorder (PTSD). The company provides a virtual care center that enables trauma survivors to receive cognitive processing therapy from PTSD-trained therapists in the comfort and privacy of their homes. Nema Health's approach aims to offer effective and lasting relief for those dealing with the impacts of trauma.

Petfolk is a veterinary care provider that reimagines the traditional approach to pet healthcare by integrating in-person visits with virtual consultations. The company aims to enhance the communication between pet owners and veterinarians by offering a comprehensive range of services that cater to both scheduled on-site care and remote consultations. Petfolk emphasizes high-quality, accessible care delivered by a team of compassionate veterinarians, utilizing advanced technology to facilitate interactions. This model enables pet owners to strengthen their relationships with both their pets and the veterinary professionals who care for them.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.

Elion Therapeutics is a biotechnology company dedicated to addressing life-threatening invasive fungal infections (IFIs). The company develops innovative treatments by enhancing the existing Amphotericin B drug, aiming to provide a broad spectrum of antifungal options that are non-toxic to mammalian cells. Elion's approach is grounded in mechanistic insights, which facilitate the targeted optimization of natural compounds for improved therapeutic efficacy. Through its focus on clinical research and development, Elion seeks to deliver safer and more effective treatments for patients suffering from serious fungal infections.

Mereo Biopharma, based in London and founded in 2015, specializes in developing and commercializing innovative therapeutics for rare diseases and cancer. The company addresses the challenges faced by large pharmaceutical firms in resource allocation for drug development, particularly for candidates beyond Phase 2 trials. Mereo has acquired a mid-late stage portfolio of three well-characterized products from Novartis Pharmaceuticals, each backed by robust pre-clinical and proof-of-concept clinical data. The company focuses on transforming patient outcomes through its pipeline of drugs targeting significant unmet medical needs. Mereo leverages its team's expertise in selecting and advancing product opportunities and collaborates with ICON, a leading global contract research organization, to enhance its operational efficiency. Mereo aims to progress its products through critical development milestones before considering partnerships or commercialization, particularly in orphan disease indications.

R3 Vascular specializes in developing and manufacturing innovative medical devices aimed at treating peripheral arterial disease. The company focuses on bioresorbable scaffold technology, specifically creating vascular scaffolds that incorporate a sirolimus coating known for its anti-inflammatory properties. This technology is designed to balance strength and flexibility, enhancing treatment outcomes for patients. One of their notable products, the magnitude BRS device, is recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of just 98 microns across various diameters. Through its proprietary polymer technologies, R3 Vascular aims to improve the management of peripheral arterial diseases, particularly in challenging areas such as below the knee.

BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Actio Biosciences focuses on the development of precision medicines tailored for homogeneous rare patient populations. The company is engaged in creating a pipeline of innovative drugs aimed at treating rare diseases, with the potential to extend their application to more common illnesses. By utilizing biotechnology to modulate the activity of proteins linked to rare diseases, Actio Biosciences aims to enhance the likelihood of clinical success and deliver effective treatments for conditions that are often difficult to cure. Their commitment to addressing both rare and common diseases positions them to make a significant impact in the field of medicine.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Ray Therapeutics is a company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. By creating technology that enhances the understanding of rare retinal conditions, the company strives to empower healthcare professionals to effectively diagnose, cure, and manage inherited retinal diseases. Through its commitment to advancing optogenetics, Ray Therapeutics seeks to improve the quality of life for those affected by these debilitating conditions.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Cortica Inc. is a company dedicated to providing neurological therapies for children facing autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers tailored treatment programs that are informed by a comprehensive understanding of each child's neurobiology and developmental profile. The company operates multiple centers across California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village. Cortica's services encompass a wide range of assessments and therapies, including diagnoses for autism, ADHD, and developmental delays. Treatment options available include gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and various therapeutic interventions such as ABA therapy, parent coaching, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company provides these services through in-home, in-clinic, and telehealth modalities.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

IronMatt's mission is to build a network committed to providing assistance to reduce family hardship, and fund pediatric brain tumor research, and patient care.

Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages novel protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By utilizing multiple therapeutic modalities, Perceive Biotherapeutics seeks to provide medical professionals with effective solutions for improving eye health and preventing vision loss.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Abeona Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing gene and cell therapies for severe, life-threatening rare genetic diseases. The company's leading programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102 and ABO-101, which are AAV-based gene therapies targeting Sanfilippo syndrome types A and B, respectively. Additional therapies under development include ABO-201 and ABO-202 for Batten disease, ABO-401 for cystic fibrosis, and ABO-5OX for genetic eye disorders. Abeona also operates the AIM Vector Platform, which focuses on advancing gene therapy delivery methods using next-generation AAV capsids. The company is engaged in a licensing agreement with REGENXBIO for gene therapies addressing multiple genetic disorders. Founded in 1974 and headquartered in New York, Abeona has a fully operational manufacturing facility that supports its preclinical and clinical research efforts.

Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Humanity Health is a platform dedicated to supporting underrepresented leaders in healthcare and life sciences by facilitating career advancement and talent acquisition. The company employs a personalized service model to provide women and people of color with access to career-accelerating opportunities and valuable introductions. It also assists employer partners in identifying, engaging, and recruiting diverse healthcare talent, leading to more inclusive hiring outcomes. The Humanity Talent Network (HTN), a private membership network, serves to amplify and connect experienced underrepresented professionals, helping them excel in competitive executive roles, board positions, and entrepreneurial opportunities. Through its proprietary screening technology and leadership development programs, Humanity Health aims to transform the landscape of healthcare recruitment and promote diversity within the industry.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

UTR Therapeutics Inc is an IND stage biotechnology company advancing mRNA Overwriting which is a spin out from City University of New York and Harvard Medical School.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Apertura Gene Therapy is a biotechnology company focused on developing innovative genetic medicines aimed at treating intractable diseases with limited treatment options. The company specializes in the engineering of adeno-associated virus (AAV) capsids that effectively bind to the human Transferrin Receptor 1 (TfR1), facilitating intravenous delivery of therapeutics through receptor-mediated transcytosis across the blood-brain barrier. This approach allows for broad penetration of the central nervous system. In addition to AAV capsids, Apertura also develops regulatory elements and therapeutic payloads to address challenges related to cellular access, gene expression, pre-existing immunity, and manufacturability. By collaborating with corporate and academic partners, Apertura is committed to advancing gene therapy and improving outcomes for patients suffering from debilitating diseases.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

Lark is a developer of a virtual chronic disease prevention and management platform that offers personalized support and counseling to users. Utilizing advanced artificial intelligence alongside human coaches and connected devices, Lark provides real-time, 24/7 assistance, helping individuals make healthier choices and manage chronic conditions effectively. The company has established CDC-recognized programs, including its Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program, which collectively serve 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in 11 peer-reviewed journals and analyst reports. Founded in 2011 by Julia Hu and Jeff Zira, Lark is headquartered in Mountain View, California.

DeepSight Technology is a health technology company focused on advancing diagnostic medical imaging. By leveraging proprietary sensing technology, the firm combines patented hardware, software, and artificial intelligence to significantly enhance image quality and increase the depth penetration of medical ultrasounds. This innovation aims to make diagnostic imaging safer, faster, more affordable, and more accessible, ultimately benefiting public health and well-being. DeepSight's advancements enable healthcare enterprises to utilize enhanced ultrasound capabilities, which can lead to improved diagnostic outcomes.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

ARS Pharmaceuticals, Inc., established in 2015 and headquartered in San Diego, California, is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. The company has created a novel intranasal epinephrine spray known as neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy utilizes a proprietary formulation that includes an absorption enhancer called Intravail, enabling it to deliver epinephrine effectively and rapidly through the nasal mucosa. This unique technology provides a convenient, reliable, and easy-to-use alternative for individuals at risk of life-threatening allergic reactions due to food, medications, or insect stings.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

Novocardia is focused on transforming the delivery of cardiovascular care to enhance patient outcomes for those suffering from heart and vascular diseases. The company operates a cardiovascular care delivery network that aims to improve the quality and value of care provided to patients. By equipping cardiologists with essential tools and fostering collaborative relationships with health plans and primary care providers, Novocardia facilitates the transition to value-based care. Its platform incorporates various capabilities, including quality and process improvement initiatives and technology-enabled care delivery, to ensure that patients receive comprehensive and effective treatment, ultimately helping them lead longer and healthier lives.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Talkspace is a behavioral healthcare company that provides online therapy services through its technology platform, connecting users with licensed therapists, psychologists, and psychiatrists. The platform allows for confidential communication and unlimited messaging therapy, enabling individuals to seek help for various mental health conditions without the need for in-person appointments. This approach caters to those who may find it difficult to open up in traditional therapy settings or who face financial barriers to accessing care. Talkspace serves a diverse clientele, including health plans, enterprises, and individual subscribers, generating revenue primarily from payor and direct-to-enterprise clients. The company focuses on delivering quality mental health support, aiming to improve the well-being of its users globally.

Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Established in 2018 and located in Menlo Park, California, the company employs advanced platforms such as engineered partial agonists and orthogonal cell therapies. Its Synthekine Platform utilizes surrogate agonists instead of traditional mutant cytokines, allowing for the creation of therapeutics that enhance efficacy while minimizing side effects. The product pipeline includes STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy targeting CD-19, along with STK-012, which consists of partial agonists of IL-2. Synthekine aims to revolutionize treatment paradigms by harnessing the principles of cytokine partial agonism and immunological specificity, leading to novel immunotherapies that improve patient outcomes.

CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

GH Research PLC is a clinical-stage biopharmaceutical company that aims to transform the treatment of psychiatric and neurological disorders. The company is primarily focused on developing novel and proprietary therapies based on 5-MeO-DMT, a compound known as Mebufotenin, to address the needs of patients suffering from Treatment-Resistant Depression (TRD). Through its innovative approach, GH Research seeks to provide new therapeutic options for individuals who have not responded to conventional treatments.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.

Twill is a healthcare platform focused on enhancing mental and physical wellness. It offers a software solution that employs web and mobile technology to evaluate users' happiness through both subjective and objective assessments. The platform includes various programs and games designed to promote healthier mindsets. By addressing issues such as stress, depression, anxiety, and social isolation, Twill aims to support individuals, employers, and care delivery systems in managing the challenges associated with chronic illness.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.